Report cover image

Middle East Cancer And Tumor Marker Assays Market Size, Share & Trends Analysis Report By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer), By Biomarker Type, By End Use, By Country, And Segment Forecasts, 2025 - 2033

Publisher Grand View Research
Published Nov 10, 2025
Length 130 Pages
SKU # GV20649542

Description

Middle East Cancer And Tumor Marker Assays Market Summary

The Middle East cancer and tumor marker assays market size was estimated at USD 228.74 million in 2024 and is expected to reach USD 579.12 million by 2033, growing at a CAGR of 11.66% from 2025 to 2033. The rising incidence of cancer in the Middle East, growing awareness through campaigns, and advances in diagnostic technologies are contributing to the market's growth. For instance, in June 2025, M42, AstraZeneca & SOPHiA GENETICS together launched a liquid biopsy initiative in the UAE. Furthermore, in a major advancement for precision oncology, M42 (UAE) collaborated with AstraZeneca (UK) and SOPHiA GENETICS (Switzerland) to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of cancers.

This strategic collaboration reflects a broader regional trend toward the adoption of precision medicine and molecular diagnostics, which is expected to significantly increase demand for tumor marker assays. Governments across the Middle East are increasing their investments in healthcare infrastructure and national cancer screening programs, enabling earlier detection and improved patient outcomes. Furthermore, as advanced immunoassay platforms become more widely available and private diagnostic laboratories expand, access to high-sensitivity biomarker tests improves. As patient awareness grows and clinicians increasingly rely on biomarker-driven treatment decisions, incorporating tumor marker assays into routine oncology workflows becomes more common, thereby accelerating market growth.

Furthermore, campaigns encourage people to undergo regular screenings and increase demand for advanced diagnostic tools, such as tumor marker assays. As awareness grows, more patients seek timely diagnostic services, prompting healthcare providers to implement biomarker-based testing solutions that enable accurate and early-stage detection and monitoring, driving market growth. For instance, in August 2023, the Qatar Red Crescent Society (QRCS) launched a fundraising campaign to provide life-saving medical care for cancer patients in northern Syria.

Middle East Cancer And Tumor Marker Assays Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 - 2033. For this report, Grand View Research has segmented the Middle East cancer and tumor marker assays market report based on cancer type, biomarker type, end use, and country:
  • Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Ovarian Cancer
  • Others
  • Biomarker Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Genetic/Genomic biomarkers
  • Protein biomarkers
  • Epigenetic biomarkers
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals and Cancer Centers
  • Diagnostic Laboratories
  • Others
  • Country Outlook (Revenue, USD Million, 2021 - 2033)
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar
  • Rest of Middle East
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

130 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Market Definitions
1.2. Country Scope
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Cancer Type Snapshot
2.3. Biomarker Type Snapshot
2.4. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.2. Market Restraint Analysis
3.4. Business Environment Analysis
3.4.1. PESTLE Analysis
3.4.2. Porter’s Five Forces Analysis
3.5. COVID-19 Impact Analysis
Chapter 4. Cancer Type Business Analysis
4.1. Cancer and Tumor Marker Assays Market: Cancer Type Movement Analysis, 2024 & 2033
4.2. Breast Cancer
4.2.1. Tumor Marker Tests Market, 2021 - 2033 (USD Million)
4.3. Lung Cancer
4.3.1. Lung Cancer Market, 2021 - 2033 (USD Million)
4.4. Colorectal Cancer
4.4.1. Colorectal Cancer Market, 2021 - 2033 (USD Million)
4.5. Prostate Cancer
4.5.1. Prostate Cancer Market, 2021 - 2033 (USD Million)
4.6. Ovarian Cancer
4.6.1. Ovarian Cancer Market, 2021 - 2033 (USD Million)
4.7. Others
4.7.1. Others Market, 2021 - 2033 (USD Million)
Chapter 5. Biomarker Type Business Analysis
5.1. Cancer and Tumor Marker Assays Market: Biomarker Type Movement Analysis, 2024 & 2033
5.2. Genetic/Genomic Biomarkers
5.2.1. Genetic/Genomic Biomarkers Market, 2021 - 2033 (USD Million)
5.3. Protein Biomarker
5.3.1. Protein Biomarker Market, 2021 - 2033 (USD Million)
5.4. Epigenetic Biomarkers
5.4.1. Epigenetic Biomarkers Market, 2021 - 2033 (USD Million)
5.5. Others
5.5.1. Others Market, 2021 - 2033 (USD Million)
Chapter 6. End Use Business Analysis
6.1. Cancer and Tumor Marker Assays Market: End Use Movement Analysis, 2024 & 2033
6.2. Hospitals and Cancer Centers
6.2.1. Hospitals and Cancer Centers Market, 2021 - 2033 (USD Million)
6.3. Diagnostic Laboratories
6.3.1. Diagnostic Laboratories Market, 2021 - 2033 (USD Million)
6.4. Others
6.4.1. Others Market, 2021 - 2033 (USD Million)
Chapter 7. Country Business Analysis
7.1. Country Market Snapshot
7.2. Saudi Arabia
7.2.1. Saudi Arabia Cancer and Tumor Marker Assays Market, 2021 - 2033 (USD Million)
7.2.2. Key Country Dynamics
7.2.3. Regulatory Framework
7.2.4. Competitive Scenario
7.3. UAE
7.3.1. UAE Cancer and Tumor Marker Assays Market, 2021 - 2033 (USD Million)
7.3.2. Key Country Dynamics
7.3.3. Regulatory Framework
7.3.4. Competitive Scenario
7.4. Kuwait
7.4.1. Kuwait Cancer and Tumor Marker Assays Market, 2021 - 2033 (USD Million)
7.4.2. Key Country Dynamics
7.4.3. Regulatory Framework
7.4.4. Competitive Scenario
7.5. Oman
7.5.1. Oman Cancer and Tumor Marker Assays Market, 2021 - 2033 (USD Million)
7.5.2. Key Country Dynamics
7.5.3. Regulatory Framework
7.5.4. Competitive Scenario
7.6. Qatar
7.6.1. Qatar Cancer and Tumor Marker Assays Market, 2021 - 2033 (USD Million)
7.6.2. Key Country Dynamics
7.6.3. Regulatory Framework
7.6.4. Competitive Scenario
Chapter 8. Competitive Landscape
8.1. Company/Competition Categorization
8.2. Strategy Mapping
8.3. Company Market Share Analysis, 2024
8.4. List of Key Certification Providers/Scheme Owners
8.5. Company Profiles/Listing
8.5.1. F. Hoffmann-La Roche AG
8.5.1.1. Company overview
8.5.1.2. Financial performance
8.5.1.3. Product benchmarking
8.5.1.4. Strategic initiatives
8.5.2. Thermo Fisher Scientific, Inc.
8.5.2.1. Company overview
8.5.2.2. Financial performance
8.5.2.3. Product benchmarking
8.5.2.4. Strategic initiatives
8.5.3. Illumina, Inc.
8.5.3.1. Company overview
8.5.3.2. Financial performance
8.5.3.3. Product benchmarking
8.5.3.4. Strategic initiatives
8.5.4. QIAGEN
8.5.4.1. Company overview
8.5.4.2. Financial performance
8.5.4.3. Product benchmarking
8.5.4.4. Strategic initiatives
8.5.5. Bio-Rad Laboratories, Inc.
8.5.5.1. Company overview
8.5.5.2. Financial performance
8.5.5.3. Product benchmarking
8.5.5.4. Strategic initiatives
8.5.6. Agilent Technologies, Inc.
8.5.6.1. Company overview
8.5.6.2. Financial performance
8.5.6.3. Product benchmarking
8.5.6.4. Strategic initiatives
8.5.7. Sysmex Corporation
8.5.7.1. Company overview
8.5.7.2. Financial performance
8.5.7.3. Product benchmarking
8.5.7.4. Strategic initiatives
8.5.8. Abbott
8.5.8.1. Company overview
8.5.8.2. Financial performance
8.5.8.3. Product benchmarking
8.5.8.4. Strategic initiatives
8.5.9. bioMérieux
8.5.9.1. Company overview
8.5.9.2. Financial performance
8.5.9.3. Product benchmarking
8.5.9.4. Strategic initiatives
8.5.10. Myriad Genetics
8.5.10.1. Company overview
8.5.10.2. Financial performance
8.5.10.3. Product benchmarking
8.5.10.4. Strategic initiatives

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us